CoChat

Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor

Open access
Schwartz, Thomas L., Siddiqui, Umar A., Stahl, Stephen M. · 2011 · Therapeutic Advances in Psychopharmacology
Cited by 55

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: Vilazodone is the latest US Food and Drug Administration approved antidepressant agent available in the USA. Its putative mechanism of antidepressant action enhances the release of serotonin across the brain’s serotonergic pathways specifically by inhibiting the serotonin transporter, similar to a selective serotonin reuptake inhibitor (SSRI), and simultaneously stimulating serotonin-1a receptors via partial agonism, similar to the anxiolytic buspirone. This combined activity in the single vilazodone agent has been termed by the authors as being a serotonin partial agonist and reuptake inhibitor or (SPARI). Methods: A MEDLINE and Internet search was conducted and the resultant preclinical and clinical evidence was reviewed . The authors attempt to review laboratory data, animal model data and human trial data to develop a translational theory on the mechanism of antidepressant action of this agent and also its adverse effect potential. Results: Randomized, controlled empirical data for vilazodone have gained it approval for treating major depressive disorder. It combines two well known pharmacodynamic mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against other antidepressants have been published, the efficacy data for vilazodone appear comparable to other known antidepressants, with similar gastrointestinal side effects to SSRI or serotonin norepinephrine reuptake inhibitor (SNRI) antidepressants, but possibly with a lower incidence of sexual side effects and weight gain. Discussion: Vilazodone will lend itself to the current armamentarium in the treatment of major depressive disorder and may hold promise for patients who cannot tolerate other antidepressants. Its unique SPARI mechanism of action could also be efficacious for patients who do not respond to SSRI or SNRI antidepressant monotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2045125311409486

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 29

  1. 10.1016/j.ejphar.2004.09.009 · DOI
  2. APA, 2000, American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th edn text revision
  3. APA, 2010, Am J Psychiatry, 150, 1
  4. Barowsky J., 2006, Psychiatry (Edgmont), 3, 42
  5. 10.1016/S0014-2999(96)00999-5 · DOI
  6. 10.4088/JCP.v67n0514 · DOI
  7. 10.1111/j.1755-5949.2008.00067.x · DOI · Paper page
  8. 10.1038/sj.bjp.0703496 · DOI
  9. 10.1021/jm040793q · DOI · Paper page
  10. 10.1016/j.pbb.2003.09.020 · DOI
  11. Hudziak J., 2005, Buspirone
  12. 10.1016/j.ejphar.2005.01.018 · DOI
  13. Khan, A., Cutler, A.J., Kajdasz, D.K., Gallipoli, S, Athanasiou, M, Robinson, D.S. et al . (2011) A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder. J Clin Psychiatry 72: 441–447. · DOI · Paper page
  14. 10.1007/s002130100703 · DOI
  15. Othmer E., 1987, J Clin Psychiatry, 48, 201
  16. 10.1124/jpet.102.034280 · DOI
  17. 10.1016/0165-0270(85)90031-7 · DOI · Paper page
  18. Pies R., 1998, Handbook of Essential Psychopharmacology
  19. 10.1016/S0969-8051(00)00120-7 · DOI
  20. 10.4088/JCP.08m04637 · DOI · Paper page
  21. 10.1016/j.ejphar.2005.05.039 · doi:10.1016/j.ejphar.2005.05.039
  22. 10.1176/appi.ajp.2009.09121768 · DOI
  23. Schwartz T.L., 2007, P&T, 32, 28
  24. Schwartz T.L. and Stah, S.M. (2010) Optimizing Antidepressant Management of Depression: current Status and Future Perspectives Vol. 27, 9th edn. Basel: Karger, 254–267. · DOI
  25. 10.1358/dof.2001.026.03.611242 · DOI
  26. Stahl S., 2008, Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd edn
  27. 10.4088/JCP.09bs05697blu · DOI
  28. Stahl S., 2011, Essential Psychopharmacology: the Prescriber's Guide, 4th edn
  29. 10.1017/S1092852900020307 · DOI · Paper page

Cited by

Metadata

Authors
Schwartz, T. L., Siddiqui, U. A., & Stahl, S. M.
Venue
Therapeutic Advances in Psychopharmacology
Published
2011-05-31
Volume
1
Issue
3
Pages
81-87
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W2046233567
Cited by
55
References
6
FWCI
1.46
Type
journal article
Language
en
Open access
bronze
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.